U.S. flag

An official website of the United States government, Department of Justice.

The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients

NCJ Number
307170
Date Published
2023
Length
9 pages
Annotation

This study found that only some autosomal dominant polycystic kidney disease (ADPKD) patients need a native nephrectomy in the context of a restrictive nephrectomy policy in the workup for kidney transplantation.

Abstract

This study indicates that with a restrictive nephrectomy policy in the workup for kidney transplantation, only some autosomal dominant polycystic kidney disease (ADPKD) patients need a native nephrectomy. There is no consensus if nor when a native nephrectomy should be performed in the workup for kidney transplantation in ADPKD patients. In the authors’ PKD Expertise Center, a restrictive approach is pursued in which nephrectomy is performed only in patients with severe complaints, i.e., in case of serious volume-related complaints, lack of space for the allograft, recurrent cyst infections, persistent cyst bleedings, or chronic refractory pain. The authors analyzed in a retrospective cohort study whether this approach is justified.  All ADPKD patients who received kidney transplantation between January 2000 and January 2019 were reviewed. Patients were subdivided into three groups: no nephrectomy (no-Nx), nephrectomy performed before (pre-Tx), or after kidney transplantation (post-Tx). Simultaneous nephrectomy together with transplantation were not performed in the center. The study included 391 patients (54 ± 9 years, 55% male). The majority of patients did not undergo a nephrectomy (n = 257, 65.7%). A nephrectomy was performed pre-Tx in 114 patients (29.2%). After Tx, nephrectomy was performed in only 30 patients (7.7%, median 4.4 years post-Tx). Surgery-related complication rates did not differ between both groups (38.3% pre-Tx vs. 27.0% post-Tx, p = 0.2), nor were there any differences in 10-year patient survival (74.4% pre-Tx vs. 80.7% post-Tx vs. 67.6% no-Nx, p = 0.4), as well as in 10-year death-censored graft survival (84.4% pre-Tx vs. 85.5% post-Tx vs. 90.0% no-Nx, p = 0.9). 

Date Published: January 1, 2023